Predictive and prognostic properties of TB-LAM among HIV-positive patients initiating ART in Johannesburg, South Africa by d’Elia, Alexander et al.




Predictive and prognostic properties of TB-LAM among HIV-positive patients initiating 
ART in Johannesburg, South Africa 
 
Alexander d’Elia1, Denise Evans2,&, Lynne McNamara3, Rebecca Berhanu2,4, Ian Sanne3,4, Elisabet Lönnermark1 
 
1Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, 40032, Sweden, 2Health Economics and Epidemiology Research 
Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 
2193, South Africa, 3Clinical HIV Research Unit, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, 
Johannesburg, 2193, South Africa, 4Right To Care, Helen Joseph Hospital, Perth Road, Johannesburg, 2092, South Africa 
 
&Corresponding author: Denise Evans, Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical 
Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 2193, South Africa        
 
Key words: Antiretroviral therapy, HIV, lipoarabinomannan, Mycobacterium, TB LAM, South Africa 
 
Received: 05/01/2015 - Accepted: 26/08/2015 - Published: 03/09/2015 
 
Abstract  
While the diagnostic properties of the TB LAM urine assay (LAM) have been well-described, little is known about its predictive and prognostic 
properties at ART initiation in a routine clinic setting. We describe the predictive and prognostic properties of LAM in HIV-positive patients initiating 
ART at an urban hospital in Johannesburg, South Africa. Retrospective study of HIV-positive adults (>18 years) who initiated standard first-line 
ART between February 2012 and April 2013 and had a LAM test at initiation. In HIV-positive patients with no known TB at ART initiation, we 
assessed the sensitivity, specificity and positive/negative likelihood ratios of LAM to predict incident TB within 6 months of ART initiation. In 
addition, in patients with a TB diagnosis and on TB treatment <3 months at ART initiation, we measured the CD4 response at 6 months on ART. Of 
the 274 patients without TB at ART initiation, 65% were female with median CD4 count of 213 cells/mm3. Among the 14 (5.1%) patients who 
developed active TB, none were urine LAM +ve at baseline. LAM had poor sensitivity (0.0 % 95 % CI 0.00-23.2) to predict incident TB within 6 
months of initiation. We analyzed 22 patients with a confirmed TB diagnosis at initiation separately. Of these, LAM +ve patients (27%) showed 
lower CD4 gains compared to LAM negative patients (median increase 103 vs 199 cells/mm3; p=0.08). LAM has limited value for accurately 
predicting incident TB in patients with higher CD4 counts after ART initiation. LAM may help identify TB/HIV co-infected patients at ART initiation 
who respond more slowly to treatment and require targeted interventions to improve treatment outcomes. Larger studies with longer patient 
follow-up are needed. 
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Tuberculosis (TB) is estimated by the World Health Organization 
(WHO) to affect about one third of the world population globally [1]. 
Up to 70% of people with active TB disease are HIV positive and TB 
is the primary cause of HIV-related mortality in sub-Saharan Africa 
[1-3]. Several studies have shown that TB co-infection increases the 
risk of HIV progression and death, particularly if the HIV disease is 
untreated [3]. Efficient TB screening at baseline is associated with a 
considerable reduction in the risk of incident TB and associated 
deaths during the initial months of treatment with ART [4]. If ART is 
started with active TB infection untreated, patients are at risk of 
developing immune reconstitution inflammatory syndrome (IRIS). 
This is a condition resulting from rapid restoration of immune 
responses to opportunistic infections, causing either deterioration of 
a treated infection or presentation of a previously sub-clinical 
infection and can result in significant morbidity [5]. TB in patients 
initiating ART is frequently undiagnosed [6]. We therefore proposed 
to determine the predictive and prognostic value of the LAM assay 
in a routine clinic setting, to assess the risk of incident TB in 
patients initiating ART who may go untreated for active TB infection.  
 
The recently introduced Alere Determine TB-LAM assay 
(DetermineTM TB-LAM urine lateral flow test, Alere Inc., Waltham, 
MA, USA) is an ELISA-based urine sample test that detects 
lipoarabinomannan (LAM), a glycolipid found in the cell wall of 
Mycobacterium tuberculosis. Compared with current diagnostic 
methods, detection of LAM antigens in urine has several advantages 
including that the samples are simple to collect, process and store. 
The test is inexpensive, has a short turnaround time and can be 
performed at point of care without expensive equipment and highly 
trained personnel [7]. Recent work has highlighted the importance 
of adequate point-of-care methods of diagnosis so that patients can 
be treated at local clinics when first presenting for treatment [8]. 
Since these clinics often lack resources, simplicity and affordability 
are very important [7,9]. The LAM assay works best in HIV-infected 
patients with advanced immunosuppression where it can help 
diagnose TB and reduce treatment delay [5,9] but performs very 
poorly as a diagnostic test in patients with a CD4 count >200 
cells/mm3. While the diagnostic properties of LAM have been well-
described, little is known about other potential benefits such as the 
predictive and prognostic properties of routine use at ART initiation 
in resource limited settings. Recent studies have shown that LAM 
may be a valuable tool to monitor anti-TB therapy response and 
have investigated whether LAM results before and after treatment 
are predictive of mortality [10]. If LAM is reliable it may be useful in 
identifying those at risk of IRIS, specifically in those initiating ART 
but who do not receive treatment for active TB. We aimed to 
determine if LAM at ART initiation could accurately predict the 
development of incident TB within the first 6 months of ART in HIV 
positive patients. In addition, we measured the CD4 response at 6 
months on ART in patients with a confirmed TB diagnosis at ART 
initiation and on anti-TB treatment for <3 months (<90 days), 





This was a retrospective analysis of data from a prospective cohort 
of HIV-infected adults initiating ART at the Themba Lethu Clinic 
(TLC), Johannesburg, South Africa. The clinic Cohort has been 
described elsewhere [11]. Patients at TLC are initiated on ART and 
are routinely followed-up according to the South African National 
Department of Health (SA DoH) ART guidelines [12,13]. At ART 
initiation, the patient is screened for TB and, if positive, referred to 
the TB Focal Point (TBFP), adjacent to the HIV clinic, for further 
investigation (chest radiology, Xpert MTB/RIF, sputum microscopy 
and/or culture). If TB is diagnosed, TB and ART treatment are 
initiated and followed up at the TBFP. To decrease the risk of IRIS, 
ART is generally started 2-4 weeks after TB treatment initiation.  
  
Urine samples were collected from 356 HIV+ve adults at ART 
initiation (t0) for LAM testing. Patient demographic and clinical 
characteristics were similar to those of the larger TLC cohort [11]. 
Subjects were HIV-positive ART naïve adults (≥18 years of age) 
initiated according to SA DoH ART treatment guidelines onto a 
standard first-line regimen of tenofovir (TDF), stavudine (d4T) or 
zidovudine (AZT) with lamivudine (3TC) and either efavirenz (EFV) 
or nevirapine (NVP) between February 2012 and April 2013. 
Duplicate LAM results were excluded, as were patients who did not 
meet the eligibility criteria. Only the t0 result was used and any 
follow-ups were removed. This left 344 participants in the analysis.  
  
For each sub-analysis the following criteria were used: predicting 
development of incident TB within the 6 first months of ART: (i) No 
TB treatment at ART initiation (t0) and (ii) a minimum follow-up time 
of 6 months on ART (n=274) (Figure 1). The aim was to determine 
the predictive value of the LAM assay in a routine clinic setting in 
HIV+ve patients with active TB at ART initiation but who remained 
untreated, so as to determine the risk of incident TB in these 
patients. We therefore excluded patients with active TB at ART 
initiation. CD4 response at 6 months on ART in patients with TB at 
ART initiation: (i) TB treatment for less than 90 days prior to ART 
initiation and (ii) CD4 count recorded at 6 months after t0 (n=22).  
  
Study definitions  
  
A positive LAM test was defined as a urine test result of equal or 
greater intensity than the grade 2+ cut-point [14,15]. If there was 
less or no reaction, the result was considered negative. TB at ART 
initiation (t0) was defined as having been on therapy for a period of 
<90 days prior to ART initiation. Incident TB was defined as a new 
TB diagnosis (condition and start date) or record of TB treatment 
(drugs and start date) in any of the study databases within 6 
months after t0 (<180 days). Incident TB was diagnosed by smear 
microscopy, culture, Xpert MTB/RIF, radiology and clinical features.  
  
Data collection  
  
Longitudinal clinical and laboratory data was obtained from the 
National Health Laboratory Service (NHLS), the TB Focal Point 
Information System (FIS) and the electronic patient management 
system, TherapyEdge-HIVTM, at the site. LAM tests were performed 
in the Department of Internal Medicine at the University of the 
Witwatersrand and results, dates and CD4 count at t0 and 6 months 
were recorded. In addition, we reviewed paper record files from 




Descriptive analysis and summary statistics were performed with 
SPSS v22 statistical software. Patient demographics and 
characteristics were summarized using medians with interquartile 
range and proportions for categorical variables. LAM result was 
dichotomized as positive or negative. CD4 at t0 was divided into 
categories of ≤50, 50 - 100, 100 - 200, 200 - 350 and >350 
cells/mm3. Log binomial regression analysis was used to test the 
association between gender and CD4 category at t0 and LAM status. 
Among patients with recently diagnosed TB prior to ART initiation, 
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the median time difference (days) between diagnosis and t0 was 
calculated and compared by LAM result. Median and interquartile 
range was calculated for CD4 at TB treatment initiation (for use in 
sub-analysis), t0 and at 6 months and both CD4 and CD4 increase 
(continuous variables) were compared by LAM using the Mann-
Whitney U test. A p value <0.05 was considered statistically 
significant.  
  
Predicting development of incident TB within the 6 first months of 
ART: to assess the predictive properties of LAM for incident TB, we 
determined the sensitivity, specificity and likelihood ratios of LAM 
(positive or negative) at ART initiation to correctly predict patients 
who developed incident TB within 6 months of ART. Additionally, we 
conducted a sensitivity analysis in patients with no confirmed 
incident TB. Using the Mann-Whitney U test, we compared the 
median 6 month CD4 increase by LAM results (false positives vs. 
true negatives) to see if there were any differences, possibly 
suggesting undisclosed TB cases.  
  
CD4 response at 6 months on ART in patients with TB at initiation: 
the Mann-Whitney U test was used to test if there was a difference 
in the CD4 response from t0 to 6 months post-ART initiation, as 
measured by the median CD4 increase, stratified by LAM at t0. The 
same was used to compare the CD4 count at TB treatment initiation 
and the median time between TB treatment initiation and t0 across 
the LAM dichotomous variable to ensure that the groups did not 
differ significantly before t0.  
  
Approval for the study was obtained from the Human Research 
Ethics Committee (HREC) of the University of the Witwatersrand 
(Clearance certificate M10418). Written informed consent was 





The majority of the 274 patients without TB at ART initiation were 
female, and this was similar between the positive (67%) and 
negative LAM (65%) groups (p=0.932). The median CD4 count and 
age at ART initiation were 213 cells/mm3 (IQR 115 - 285) and 37.8 
years (IQR 32.3 - 44.3) respectively (Table 1). Only 44% (4/9) of 
those with a positive LAM and 28% (74/265) with a negative LAM 
reported any TB symptoms at ART initiation, including cough, fever, 
night sweats, weight loss and fatigue (p=0.281). In 54.7% 
(150/274) of patients the CD4 count was >200 cells/mm3. 
Compared to those with a negative LAM, more patients with a 
positive LAM had a CD4 count ≤50 cells/mm3 (22.2% vs. 11.3%). 
Conversely, more patients with a negative LAM had a CD4 count 
>200 cells/mm3 (55.5% vs. 33.3%). Consequently, patients with a 
CD4 count ≤50 cells/mm3 were more likely to have a positive LAM 
result compared to those with a CD4 count >200 cells/mm3 
(Relative Risk (RR) 2.4; 95% CI 0.77 - 7.25; p=0.134), although the 
estimate lacked precision and the confidence interval was wide.  
  
Predicting the development of incident TB within the 6 first 
months of ART  
  
Of the 274 patients, 9 (3.3%) had a positive LAM result at ART 
initiation and none were diagnosed with TB within 6 months 
(sensitivity 0.0%, 95% CI 0.0 - 23.2; specificity 96.5%, 95% CI 
93.5 - 98.4; negative likelihood ratio 1.04, 95% CI 1.01 - 1.06) 
(Table 1). Of the 265 patients who were LAM negative, 14 (5.3%) 
developed incident TB. Our study did not have sufficient power to 
detect a significance difference between LAM positive and LAM 
negative at ART initiation and the development of incident TB (RR 
0.92 95% CI 0.06 - 14.3; p=0.951). The median time from ART 
initiation to TB diagnosis was 22.5 days (IQR 12.8 - 69.8). Of the 14 
file-diagnosed TB cases, 8 (57.1%) were pulmonary while 6 
(42.9%) were extra pulmonary. In patients with incident TB, the 
median CD4 count at ART initiation was 117 cells/mm3 (IQR 43.0 - 
260.0), and 324 cells/mm3 (IQR 177.5 - 376.3) after 6 months; the 
difference between ART initiation and 6 months was 116 cells/mm3 
(IQR 74.3 - 198.5). Three of the 14 patients (21.4%) with TB had a 
CD4 count ≤50 cells/mm3; 2 (14.3%) had a CD4 count 51-100 
cells/mm3; 4 (28.6%) 101-200 cells/mm3 and 5 (35.7%) >200 
cells/mm3. In patients with no diagnosis of incident TB (n=260), the 
median CD4 count at ART initiation was 207 cells/mm3 (IQR 108.8 - 
270.3) and 306 cells/mm3 (IQR 202.0 - 425.3) at 6 months. The 
median increase between ART initiation and 6 months was 130 
cells/mm3 (IQR 57.5 - 202.5).  
  
CD4 response at 6 months on ART in patients with TB at 
ART initiation  
  
Twenty two patients were included in the analysis, of whom 63.6% 
were female with a median age of 35.1 years (IQR 31.7 - 38.4) 
(Table 2). At TB treatment initiation, median CD4 count for LAM 
positive (n=6) was 68 cells/mm3 (IQR 22.3 - 238.5) compared to 
144 cells/mm3 (IQR 66.3 - 175.3) (p=0.49) for LAM negative 
(n=16). At t0 the median difference in CD4 between the 2 groups 
was 70 cells/mm3 (positive 72 cells/mm3 IQR 28.5 - 223.5 vs. 
negative 142 cells/mm3 IQR 62.0 - 175.3; p=0.88). The median 
time from TB treatment initiation to t0 was 28.0 days (IQR 19.3 - 
49.3) for the LAM positive group and 21.5 days (IQR 14.5 - 51.5) 
for the negative group (p=0.51). The main outcome was the CD4 
increase during the first 6 months of ART, compared by LAM result. 
At 6 months on ART, patients who were positive at ART initiation 
increased their median CD4 count to 152 cells/mm3 (IQR 133.0 - 
274.3) compared to 316 cells/mm3 (IQR 178.5 - 425.3) in the 
negative group. At all points LAM positives had lower absolute CD4 
counts than negatives (TB treatment initiation -23 cells/mm3; t0 -
11.3 cells/mm3 and 6 months -96 cells/mm3). Patients who were 
LAM positive had a lower CD4 gain (103 cells/mm3 IQR 18.5 - 
149.0) compared to the LAM negatives (199 cells/mm3 IQR 89.3 - 
271.3), a difference of 96 cells/mm3 (p=0.08). The difference in 6 
month CD4 increase between males and females was 82 cells/mm3 





The diagnostic properties of LAM have been well-described but little 
is known about its predictive and prognostic properties at ART 
initiation. We aimed to see if screening with LAM at ART initiation 
among HIV patients could predict incident TB diagnosis within 6 
months. We analyzed CD4 response in the first 6 months of 
treatment in a sub-group of 22 patients who had already begun TB 
treatment at ART initiation to see if a positive test resulted in a 
poorer immunological response to ART. We hypothesized that 
incident TB diagnosed within 6 months of ART initiation might be 
present in an active and detectable form at initiation. A positive LAM 
test could then enable targeted interventions such as more 
aggressive investigations for TB and, in the case of 
immunosuppressed patients with undiagnosed TB, predict IRIS. 
However, results showed that LAM had poor sensitivity for this. The 
low cost and ease of use of LAM means general screening could be 
justified if the disease-dismissing properties were adequate. The 
high specificity is somewhat misleading as prevalence of disease 
was low. The negative likelihood ratio was virtually 1, indicating that 
a negative test added no information. A possible explanation for the 
poor predictive properties could be that incident TB observed during 
the 6 months was not detectable at t0. However, the results were 
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generally concordant with earlier diagnostic studies such as that by 
Lawn and colleagues, where LAM had a sensitivity of 4% in patients 
with CD4 >200 cells/mm3 when compared to a positive TB sputum 
culture [9]. This supports the poor performance of LAM in our study 
where >50% of the patients had a CD4 >200 cells/mm3. Nine 
patients were LAM positive but did not develop incident TB. It is 
possible that these were false positives due to cross-reactions with 
other proteins in the urine; 1 patient had a positive symptom screen 
1 month prior to ART initiation, however, there was no indication 
that the patient started TB treatment and 3 patients had tests 
registered in NHLS but were all negative.  
  
To determine if a positive LAM predicted a poorer immunological 
response to ART among patients who had been on TB treatment for 
3 months or less at ART initiation, we compared LAM test results 
and CD4 levels at initiation of TB treatment and ART. The numbers 
were small but we nevertheless demonstrate a noticeable difference 
in CD4 gain at 6 months post ART initiation, with higher gains 
observed in those with a negative test (p=0.08). At all points, LAM 
positives had lower absolute CD4 counts than LAM negatives. This 
could be interpreted as meaning that a more aggressive TB and/or 
poorer response to TB/ART treatment correspond to a poorer CD4 
response. Those with incident TB also showed lower gains in CD4 at 
6 months post-ART compared to those without (-28 cells/mm3). 
Studies have reported that prevalent or incident TB does not 
compromise immunological or virological response to ART [16], 
however these studies did not stratify by LAM at ART initiation. A 
study from western Kenya showed active TB to be associated with 
poorer clinical outcomes in HIV-infected African patients on ART. In 
this study, although TB patients showed an almost identical rise in 
CD4 count after ART initiation to those with no TB, the overall CD4 
count at 1 year was lower among patients with active TB (251 vs 
269 cells/µl) [17]. Other possible reasons for the observed trend 
may be TB therapy-ART interactions, co-morbidity to TB in other 
diseases and poor adherence to ART or TB therapy. 
 
Limitations: Patients already on TB treatment at ART initiation 
were excluded and, instead, formed the sample for the second 
objective. The prevalence of disease in the predictive study was, 
therefore, low (5.1% 95% CI 2.82 - 8.43%). This differs from 
previous reports from the same clinic (n=21,101; 11.9% prevalent 
TB) [11] and a study on 6 month IRIS by Hermans and colleagues 
in a similar setting that measured a prevalence of 8.8% [18]. Other 
reasons for the low prevalence could be that patients at TLC are 
initiated on ART at a higher CD4 count than average (median 213 
cells/mm3 IQR 115 - 285), and are, thus, generally healthier. Also, 
since TLC is a part of Helen Joseph Hospital, the sickest patients are 
initiated on ART in the wards instead of at TLC. The primary 
limitation of this study is missing data on TB testing at baseline. 
Among those that were urine LAM positive, there may have been an 
underlying active TB infection. The screening for TB may have 
missed some patients with active disease. From the main cohort 
(n=356), 13 (3.7%) patients had died, 35 (9.8%) were lost from 
care and 23 (6.5%) had transferred out so it was not possible to 
ascertain the impact on mortality or if any cases of active TB were 
missed. Data regarding Isoniazid Preventive Therapy (IPT) was not 
available. During the study period, 14% of patients were lost to 
follow up, limiting the follow-up time for diagnosis of incident TB. 






We concluded that LAM has limited value for predicting incident TB 
accurately in patients with higher CD4 counts after ART initiation. In 
this study we demonstrated that LAM may help identify TB/HIV co-
infected patients at ART initiation who respond more slowly to 
treatment and require targeted investigations (e.g. drug 
interactions, adherence counselling, adverse events, treatment 
failure etc.). Larger studies with longer patient follow-up are 
required to further assess relations and co-factors, understand why 
patients who are LAM positive at ART initiation have lower CD4 
gains and determine if the inexpensive LAM test can be added to 
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Table 1: Characteristics of patients at TB-LAM UA testing (n=274)  
Table 2: Characteristics of TB-LAM patients with recently diagnosed 
active TB (n=22)  
Figure 1: Schematic representation showing the patients included. 
A total of 356 patients had a TB LAM test at ART initiation. Twelve 
patients were excluded and the remaining 344 included in the 
analysis. Two hundred and seventy four patients were not on TB 
treatment at ART initiation (t0) and had a minimum follow-up time 
of 6 months after ART initiation while 22 patients had been on TB 
treatment for less than 90 days prior to ART initiation and had a 
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Figure 1: Schematic representation showing the patients included. A total of 356 patients had a TB LAM 
test at ART initiation. Twelve patients were excluded and the remaining 344 included in the analysis. Two 
hundred and seventy four patients were not on TB treatment at ART initiation (t0) and had a minimum 
follow-up time of 6 months after ART initiation while 22 patients had been on TB treatment for less than 
90 days prior to ART initiation and had a CD4 count recorded at 6 months after ART initiation 
 
 
Table 1: Characteristics of patients at TB-LAM  testing (n=274) 
  All TB-LAM positive 
N=9 
TB-LAM  negative 
N=265 
Gender, Female, n (%) 179 (65.3%) 6 (66.7%) 173 (65.3%) 
Age, years, median (IQR) 37.8 (32.3 - 44.3) 39.4 (33.0 - 46.3) 37.6 (32.0 - 44.2) 
CD4  cells/mm3 Median (IQR) 213 (115 - 285) 117 (43 - 260) 214 (120 - 285) 
<50 32 (11.7%) 2 (22.2%) 30 (11.3%) 
51 - 100 30 (10.9%) 1 (11.1%) 29 (10.9%) 
101 - 200 62 (22.6%) 3 (33.3%) 59 (23.3%) 
201 - 350 126 (46.0%) 2 (22.2%) 124 (46.8%) 
≥350 24 (8.8%) 1 (11.1%) 23 (8.7%) 
Outcome Confirmed active TB, n (%) 14 (5.1%) 0 (0%) 14 (5.3%) 
Pulmonary, n (% of TB)  8 (57.1%) 0 (0%) 8 (57.1%) 
Extra pulmonary, n (% of TB) 6 (42.9%) 0 (0%) 6 (42.9%) 
Table 2: Characteristics of TB-LAM patients with recently diagnosed active TB (n=22) 




Gender, Female, n (%) 14 (63.6%) 4 (66.7%) 14 (63.6%) 
Age, years, median (IQR) 35.1 (31.7 - 38.4) 32.0 (31.7 - 36.2) 35.4 (31.9 - 39.1) 
CD4  cells/mm3, median 
(IQR) 
TB treatment initiation 142 (45.0 - 199.3) 68 (22.3 - 238.5) 144 (66.3 - 175.3) 
  ART initiation 141 (30.8 - 177.8) 72 (28.5 - 223.5) 142 (62.0 - 175.3) 
6 months on ART 257 (143.8 - 407.8) 152 (133.0 - 274.3) 316 (178.5 - 425.3) 
Time between TB treatment initiation and ART initiation, days, 
median (IQR) 
21.5 (16.8 - 42.5) 28.0 (19.3 - 49.3) 21.5 (14.5 - 51.5) 
Outcome - CD4 increase  
(cells/mm3), median (IQR) 
ART initiation to 6 months on 
ART 
149 (79.5 - 225.5) 103 (18.5 - 149.0) 199 (89.3 - 271.3) 
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